AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36147577
Drug: MET (MET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET (MET 1000 mg twice daily)
Trial: 37264767
Drug: liraglutide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 3.0 mg
Trial: 33287713
Drug: Standard anti-TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anti-TB treatment
Trial: 38749259
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine
Trial: 32208231
Drug: Exposure and
RxNorm normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure and response prevention (ERP) treatment
Trial: 35194648
Drug: Ledipasvir/Sofosbuvir (once-daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/Sofosbuvir (once-daily)
Trial: 34487346
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (Imm)
Trial: 34847453
Drug: Nature-based program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nature-based program (2 hours, twice a week for three consecutive weeks)
Trial: 32945875
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention (motivational enhancement therapy and cognitive behavioral therapy, 6 in-person sessions of 1 hour each and 3 optional group sessions)
Trial: 32915099
Drug: L‐DRSEQ‐SRA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐DRSEQ‐SRA in the non‐drinking group
Trial: 32915099
Drug: L‐DRSEQ‐SRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐DRSEQ‐SRA
Trial: 33560877
Drug: PTR plus
RxNorm normalized name: PTR-01
DrugBank: PTR-01 (DB17900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTR plus chemotherapy
Trial: 36498519
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (100 micrograms)
Trial: 33156201
Drug: Zuspan regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuspan regimen (4‐g IV loading dose, then a 1‐g/h infusion)
Trial: 33156201
Drug: Alternate regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate regimen (6‐g IV loading dose, then a 2‐g/h infusion)
Trial: 34643781
Drug: nCRT (neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCRT (neoadjuvant chemoradiation therapy)
Trial: 35717156
Drug: Group Interpersonal
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Interpersonal Psychotherapy (IPT-G) delivered by community health workers (CHWs)
Trial: 35717156
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (wait-listed group)
Trial: 32924315
Drug: Angong Niuhuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angong Niuhuang pill (ANP)
Trial: 36892884
Drug: Positive Affect
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Affect Treatment (PAT)
Trial: 33872070
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg once every 3 weeks for up to 35 cycles)
Trial: 32308204
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg once daily for 6 months
Trial: 35485344
Drug: HBsAg-positive individuals
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg-positive individuals with HBV-DNA ≥2000 IU/mL
Trial: 35485344
Drug: HBsAg-positive individuals
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg-positive individuals with HBV-DNA <2000 IU/mL
Trial: 36322562
Drug: Reduced Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Nicotine Content (RNC) research cigarettes (nicotine content reduced to 0.2 mg over 18 weeks)
Trial: 35346577
Drug: Entecavir capsule
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir capsule plus Fuzheng Huayu tablet
Trial: 35346577
Drug: Entecavir capsule
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir capsule plus simulant of Fuzheng Huayu
Trial: 34270409
Drug: Multidimensional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional treatment framework (n = 28)
Trial: 35094079
Drug: Met injection
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Met injection (5 g/L Met + 7.5 g/L NaCl)
Trial: 33593769
Drug: Dihydroartemisinin/piperaquine (DP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin/piperaquine (DP) treatment
Trial: 33472172
Drug: Anserine 500
RxNorm normalized name: POTENTILLA ANSERINA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anserine 500 mg per day
Trial: 33518626
Drug: Control measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control measles vaccine (n = 85)
Trial: 35768985
Drug: ESPB +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESPB + fentanyl based intravenous patient‐controlled analgesia (IV‐PCA)
Trial: 36448621
Drug: Standard BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BP lowering treatment
Trial: 36448621
Drug: Intensive BP
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive BP lowering treatment
Trial: 35989252
Drug: 500-mg MXR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mg MXR tablet manufactured by Merck Pharmaceuticals Manufacturing (Jiangsu) Co.
Trial: 35218559
Drug: Terbutaline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (4 mg × day−1, n = 13)
Trial: 33972742
Drug: sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib (400 mg twice daily)
Trial: 33272309
Drug: Propolis supplementation
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis supplementation (300 mg Iranian green propolis extract) three times a day for 2 weeks
Trial: 36282537
Drug: risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risankizumab 150 mg (after switching from placebo)
Trial: 35404990
Drug: Structured pharmacotherapy
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured pharmacotherapy optimization intervention
Trial: 34107509
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (PPDC and HT)
Trial: 34613578
Drug: Autologous platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet-rich plasma (PRP) infusion
Trial: 38297916
Drug: Exebacase +
RxNorm normalized name: Exebacase
DrugBank: Exebacase (DB16161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exebacase + antibiotics
Trial: 38297916
Drug: Antibiotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics alone
Trial: 32271718
Drug: Antibiotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics alone (MRSA patients)
Trial: 33993501
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks until week 52
Trial: 33993501
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks until week 24, then 300 mg every 4 weeks until week 52
Trial: 33993501
Drug: Placebo (mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mometasone furoate nasal spray) until week 52
Trial: 35896277
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor-based therapy (a fixed combination of perindopril and indapamide)
Trial: 35896277
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor-based therapy
Trial: 36351735
Drug: Brief pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief pain consult (BPC) followed by telehealth physical therapy (PT) in the first 12 weeks (sequenced delivery strategy)
Trial: 36351735
Drug: Brief pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief pain consult (BPC) followed by telehealth physical therapy (PT) for non-responders (adaptive strategy)
Trial: 33174234
Drug: Full-mouth scaling
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth scaling and root planing (SRP) with adjunctive glycine powder air-polishing (GPAP)
Trial: 34823018
Drug: Metformin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,000 mg twice daily)
Trial: 38200419
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy
Trial: 32420649
Drug: Vortioxetine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (15 mg daily)
Trial: 32420649
Drug: Sertraline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (75 mg daily)
Trial: 34223077
Drug: Azithromycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (2 g, oral dose)
Trial: 33492394
Drug: Normal salt
RxNorm normalized name: SODIUM CHLORIDE 1 g ORAL TABLET [Normal Salt]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal salt diet (NSD, 6 g NaCl/day)
Trial: 34908567
Drug: Tapentadol 50
RxNorm normalized name: tapentadol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol 50 mg (Group B)
Trial: 39427924
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT)
Trial: 36397446
Drug: LJR ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJR ointment
Trial: 39197113
Drug: Ubrogepant 100
RxNorm normalized name: ubrogepant 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubrogepant 100 mg
Trial: 32573795
Drug: Ubrogepant 100
RxNorm normalized name: ubrogepant 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubrogepant 100 mg plus Sumatriptan 100 mg
Trial: 33087441
Drug: Beta Blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta Blockers (BBs)
Trial: 32181756
Drug: HD‐MAPs delivering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD‐MAPs delivering 10 μg HA
Trial: 32181756
Drug: HD‐MAPs delivering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD‐MAPs delivering 15 μg HA
Trial: 32181756
Drug: IM injection
RxNorm normalized name: filgrastim Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection of QIV (15 μg/dose)
Trial: 34750670
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (control group)
Trial: 35761306
Drug: Psychodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic Therapy (PDT)
Trial: 32385943
Drug: Calcium hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxylapatite (3.0 mL)
Trial: 36043711
Drug: Acetyl-L-carnitine (ALCAR)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALCAR) 1.5 g BID for 3 months
Trial: 35170216
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice-daily plus aspirin
Trial: 35170216
Drug: Placebo on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo on aspirin background
Trial: 34052087
Drug: Injected polyurethane
RxNorm normalized name: polyurethane-62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected polyurethane foam and gel cushions
Trial: 35219973
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy combined with trunk restraint
Trial: 33401489
Drug: Integrated depression
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated depression treatment and economic strengthening intervention
Trial: 32996347
Drug: CLS-FUERTE (multicomponent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLS-FUERTE (multicomponent behavioral Evidence-Based Treatment)
Trial: 32374423
Drug: Monthly injections
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly injections
Trial: 34542079
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation therapy (CRT)
Trial: 39231780
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (ETAU)
Trial: 34389292
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation.
Trial: 34389292
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of aspirin per day.
Trial: 33440088
Drug: Ad26.COV2.S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S vaccine (5×10^10 viral particles low dose or 1×10^11 viral particles high dose)
Trial: 33053570
Drug: Mifepristone (MFP)
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone (MFP) 50 mg
Trial: 33931997
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard early enteral nutrition treatment through nasojejunal tube).
Trial: 33721623
Drug: Myoinositol 1000
RxNorm normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myoinositol 1000 mg twice daily
Trial: 33559255
Drug: Pharmacists maintaining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists maintaining adequate antibiotic stock supply
Trial: 33559255
Drug: Antibiotics dispensed
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics dispensed upon physician recommendation
Trial: 32647023
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral antibiotics (OA) alone
Trial: 33494843
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of Na and K excretion with BMI and age
Trial: 34702183
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration (WI) with a 40 ml bolus of 0.5% Ropivacaine infiltrated at the ports and minimally invasive wound.
Trial: 35841422
Drug: LB-102 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB-102 (100 mg QD, 75 mg BID, 100 mg BID)
Trial: 34023695
Drug: Facilitated subcutaneous
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated subcutaneous immunoglobulin therapy (fSCIG)
Trial: 33957657
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin (6 milliunits/min)
Trial: 33957657
Drug: Standard-dose oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose oxytocin (2 milliunits/min)
Trial: 32419540
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) alone
Trial: 34508116
Drug: BeBo Concept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BeBo Concept exercise program (6-week physical therapy)
Trial: 36153027
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy (standard treatment, 2 weekly sessions)
Trial: 35242595
Drug: Guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-based cognitive behavioral therapy (ICBT)
Trial: 36340254
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) with drug-eluting stents
Trial: 32592897
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure (PAP) therapy during hospitalization, n = 75
Trial: 32592897
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving guideline-directed therapy for HF decompensation, n = 75
Trial: 35853675
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg IXE every 4 weeks or 2 weeks
Trial: 39213738
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT)
Trial: 36282755
Drug: Skin-to-skin contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-to-skin contact (SSC) for 1 hour daily from birth until postnatal week 5
Trial: 34630103
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg twice daily
Trial: 39476339
Drug: Once-weekly subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous semaglutide (2.4 mg)
Trial: 36150662
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for endocarditis
Trial: 36209759
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice a day for 7 days
Trial: 34128838
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice a day for 14 days
Trial: 34213584
Drug: EcN® 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcN® 320 mg, twice daily for 4 weeks and then once daily for 8 weeks (Group B)
Trial: 34213584
Drug: Levofloxacin® 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin® 500 mg once daily for 4 weeks (Group A)
Trial: 34750297
Drug: AHEU (in‐utero
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHEU (in‐utero combination antiretroviral treatment)
Trial: 34032758
Drug: Medication safety
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication safety education alone
Trial: 37457966
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccine
Trial: 38631826
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg daily
Trial: 32276883
Drug: Alfaxalone at
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone at 3.5 mg kgâ€“1
Trial: 32276883
Drug: Alfaxalone 2
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 2 mg kgâ€“1 and medetomidine 40 Î¼g kgâ€“1, reversed with atipamezole at 0.16 mg kgâ€“1
Trial: 35623880
Drug: High-calcium breakfast
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calcium breakfast from calcium citrate (∼770 mg/d)
Trial: 35623880
Drug: High-calcium breakfast
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calcium breakfast from skim milk (∼770 mg/d)
Trial: 35623880
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium breakfast (control, ∼70 mg of calcium/d)
Trial: 33268715
Drug: Ice cream
RxNorm normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice cream with azithromycin
Trial: 34228102
Drug: IV zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV zoledronic acid (ZA) 0.05 mg/kg
Trial: 38940494
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy
Trial: 32979708
Drug: Soybean (Soygan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean (Soygan 500 mg capsule)
Trial: 32979708
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (Omega-rex 1000 mg soft gel)
Trial: 38236314
Drug: Eptinezumab 300
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptinezumab 300 mg